Aptahem » 2018

Aptahem Newsletter March 2018

2018-03-21

CEO comments 2018 is very much underway, and we’re really building momentum – what a start to the year we’ve had! So much has happened in the barely three months since the beginning of the year, and I look...

Aptahem strengthens the company’s management team with the appointment of a new Chief Medical Officer in advance of the clinical program

2018-02-27

Aptahem AB (publ) is a biotechnology company that develops aptamer-based pharmaceuticals for the treatment of life-threatening conditions in which a combination of coagulation and inflammation are involved in the disease process. Aptahem is today pleased to announce the appointment...

Aptahem’s scale-up process for an efficient larger-scale manufacture of Apta-1 is finalized

2018-02-20

Aptahem AB (Aktietorget: APTA) a biotechnology company which is developing aptamer-based drugs for the treatment of life-threatening conditions in which coagulation and inflammation work together in the disease process, announces that production process of the company´s drug candidate Apta-1...

Aptahem strengthens the company´s scientific advisory board with internationally recognised and highly qualified experts in advancement of clinical studies

2018-01-17

Aptahem is today pleased to announce the recruitment to the company´s scientific advisory board of Hans Peter Schwarz and Mats Eriksson; two highly experienced and internationally recognised experts. Professor Hans Peter Schwarz, MD has previously held leading positions within...